Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24291882 | 1.00 | TK1 (0.41) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL15871887 | 1.00 | TK1 (0.41) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL23618870 | 0.91 | TK1 (0.44) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL12646692 | 0.90 | TK1 (0.42) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL19840296 | 0.90 | TK1 (0.42) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL12590107 | 0.90 | TK1 (0.42) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL12015175 | 0.90 | TK1 (0.42) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL23645690 | 0.90 | TK1 (0.39) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL24688720 | 0.90 | TYMP (0.38) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL13515629 | 0.90 | TK1 (0.40) | TK1ALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | ALIGOS THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | HAVCR2, POLRMT, DCLRE1B | TK1 175/4885ALDH1A1 4658/4885LMNA 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.